BioNTech posted IFRS Q2 revenue of €105.6 million, down 59.52% year over year, while IFRS net loss widened to €820.8 million.
IFRS diluted loss per share deepened to €3.24; IFRS R&D expenses climbed to €551 million and SG&A expenses rose to €197.8 million.
Cash, cash equivalents and security investments totaled €16.6 billion at June 30; a $1 billion ADS buyback began in May.
Full-year 2026 revenue guidance was cut to €1.6 billion-€1.9 billion; adjusted R&D guidance was lowered to €2 billion-€2.3 billion.
Guido Oelkers was named incoming CEO, due to take office by Feb. 1, 2027; the pipeline includes 14 pivotal trials, including new late-stage starts for pumitamig.
BNTX•
